ASH 2014 | Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma

Name: Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma
Uploaded: 2014-12-05T00:00:00Z
Duration: 7 min 27 s
Description: At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) presents results from the phase III AETHERA trial, which evaluated the safety and efficacy of brentuximab vedotin in preventing post-autologous stem cell transplant disease recurrence in Hodgkin lymphoma patients.

Craig Moskowitz • 5 Dec 2014

ASH 2014

Hodgkin Lymphoma Antibodies Brentuximab vedotin

AETHERA

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) presents results from the phase III AETHERA trial, which evaluated the safety and efficacy of brentuximab vedotin in preventing post-autologous stem cell transplant disease recurrence in Hodgkin lymphoma patients.